Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Digestive System Diseases

Skin and Connective Tissue Diseases

Infections

Gland and Hormone Related Diseases

Rare Diseases

Lung Neoplasms

Carcinoma

Stomach Neoplasms

Breast Neoplasms

Herpes Simplex

Pancreatic Neoplasms

Liver Neoplasms

Sarcoma

Virus Diseases

Stomach Cancer

Pancreatic Cancer

Soft Tissue Sarcoma

All Drugs and Chemicals

Immunomodulating Agents

Muromonab-CD3

Every 7-14 days,1-4 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or intraperitoneal in patients with advanced solid tumors

R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Recombinant oncolytic herpes simplex virus type 1 (R130)

Feng Pan, MD

Zhengxiang Han, MD,PhD

Zhengxiang Han, MD

20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

Evaluate the efficacy endpoints of DOR by the investigator with RECIST v1.1 and iRECIST

To characterize the safety profile of R130 injection in patients with advanced solid tumors as measured by the incidence of Grade ≥ 3 Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0)

Detection of liver and renal function, electrocardiogram, routine blood examination etc.

Detection of increased systemic immune Response markers in sera (IL2,IL4,IL6,IL8,IL10,TNFa，IFNγ, etc.) and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS)

Evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST

The Affiliated Hospital of Xuzhou Medical University

Shanghai Yunying Medical Technology

Ear, Nose, and Throat Diseases

Musculoskeletal Diseases

Mouth and Tooth Diseases

Esophageal Neoplasms

Head and Neck Neoplasms

Otorhinolaryngologic Neoplasms

Nose Neoplasms

Laryngeal Neoplasms

Pharyngeal Neoplasms

Laryngeal Diseases

Respiratory Tract Diseases

Respiratory Tract Neoplasms

Otorhinolaryngologic Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Esophageal Cancer

Laryngeal Cancer

Every 7-14 days,1-2 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral in patients with relapsed/refractory head and neck cancer

Haitao Wu, Ph.D

Jian Chen

Haitao Wu, Phd

9 participants are expected to be enrolled for this open，single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory head and neck cancer.

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer

A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Head and Neck Cancer

To characterize the safety profile of R130 injection in patients with relapsed/refractory head and neck cancer as measured by the incidence of Grade ≥ 3 Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0)

Eye & ENT Hospital of Fudan University

Nervous System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Melanoma

Brain Neoplasms

Carcinoma, Renal Cell

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Renal Cell Carcinoma

Every 7-14 days,1-2 ml R130 （concentration of 1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or intraperitoneal in patients with advanced solid tumors

Feng Pan

Peiliang Zhang

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

An Open, Single-armed, Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

To characterize the safety profile of R130 injection in patients with advanced solid tumors as measured by the incidence of Grade ≥ 3 Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0),such as fever, fatigue, flu like symptoms, chills, Injection site reaction,etc.

CT will be performed to evaluate the efficacy endpoints of DCR by the investigator with RECIST v1.1 and iRECIST. DCR (proportion of patients) = with CR +PR +SD /CR + PR +SD + PD.

The time length between the first confirmed objective response per RECIST 1.1 to the treatment and the subsequent disease progression per RECIST 1.1

Comparison of patients' quality of life before and after R130 treatment as assessed by the EORTC QLQ-30 (V3.0).

Linyi Central Hospital

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Fallopian Tube Neoplasms

Peritoneal Neoplasms

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Genital Neoplasms, Female

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Fallopian Tube Diseases

Abdominal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Peritoneal Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Fallopian Tube Cancer

Every 7-14 days,1-4 ml R130 （concentration of 1x10\^6-1x10\^8 plaque-forming Units/mL,PFU/mL）will be injected intratumoral or Intraperitioneal in patients with relapsed/refractory ovarian cancer.

R130, a modified herpes simplex virus-1 (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Jing Guo, MD,PhD

Zhongping Cheng, MD

10 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety, tolerability, and efficacy of the recombinant herpes simplex virus I, R130 in patients with relapsed/refractory ovarian cancer.

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

All serious and non-serious adverse events that occur after enrollment through 7 (+14) days after the last administration of R130 will be recorded

Detection of increased systemic immune Response markers in sera,ascites and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS)

Shanghai 10th People's Hospital

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Bronchogenic

Thoracic Neoplasms

Lung Diseases

Bronchial Neoplasms

Small Cell Lung Cancer

Feng Pan, Ph.D

Huan Chen, Bachelor

24 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory advanced solid tumors.

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

The PLA Navy Anqing Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors	NCT05860374	Sarcoma Carcinoma Breast Cancer Pancreatic Canc... Colorectal Canc... Gastric Cancer Liver Cancer Lung Cancer Gynecologic Can...	Recombinant onc...	18 Years - 75 Years	Shanghai Yunying Medical Technology
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer	NCT05830240	Head and Neck C... Esophageal Canc... Otorhinolaryngo... Ear Cancer Nose Cancer Laryngeal Cance... Pharyngeal Canc...	Recombinant onc...	18 Years - 75 Years	Shanghai Yunying Medical Technology
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors	NCT05961111	Sarcoma Carcinoma Digestive Cance... Breast Cancer Lung Cancer Brain Cancer Melanoma Gynecologic Can... Head and Neck C... Kidney Cancer	Recombinant onc...	18 Years - 75 Years	Shanghai Yunying Medical Technology
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer	NCT05801783	Ovarian Cancer Peritoneal Carc... Fallopian Tube ...	Recombinant onc...	18 Years - 75 Years	Shanghai Yunying Medical Technology
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors	NCT05886075	Lung Cancer Bronchial Cance... Non Small Cell ... Small Cell Lung... Sarcoma Colorectal Canc... Gastric Cancer Liver Cancer Breast Cancer Pancreatic Canc... Head and Neck C... Ovarian Cancer	Recombinant onc...	18 Years - 75 Years	Shanghai Yunying Medical Technology
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors	NCT05886075	Lung Cancer Bronchial Cance... Non Small Cell ... Small Cell Lung... Sarcoma Colorectal Canc... Gastric Cancer Liver Cancer Breast Cancer Pancreatic Canc... Head and Neck C... Ovarian Cancer	Recombinant onc...	18 Years - 75 Years	Shanghai Yunying Medical Technology
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer	NCT05830240	Head and Neck C... Esophageal Canc... Otorhinolaryngo... Ear Cancer Nose Cancer Laryngeal Cance... Pharyngeal Canc...	Recombinant onc...	18 Years - 75 Years	Shanghai Yunying Medical Technology

Spots Global Cancer Trial Database for recombinant oncolytic herpes simplex virus type 1 (r130)